Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum IMV Inc IMVIQ

IMV Inc. is a Canada-based company. The Company has no business operations.

GREY:IMVIQ - Post Discussion

IMV Inc > January 10 2022
View:
Post by Breakthorough1 on Jul 27, 2023 1:49pm

January 10 2022

"The study is designed to be Stage 1 is, Does pembrolizumab plus (IMV’s) mavero equal better (results) than just pembro? And if it goes forward into Stage 2, the deal originally was that Merck would co-contribute to Stage 2 … so that as we push toward registration (of a commercial trial) Merck would be involved. So the first part of the study was ours to be funded; the second part is Merck’s to be funded. The reality was that it was more cost effective to close down the basket study … and the reason we are being a little coy with our press releases and we’re obviously still involved with Merck deeply and in conversations with Merck about how they want to fund the next step in bladder cancer and the next step in MSI-H (colon cancer, other tumors with high levels of micro-satellite instability. )"
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities